Amwill Health Care Limited
BSE: AMWILL · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Amwill Health Care Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Amwill Healthcare is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of diverse pharmaceutical formulations. Its product portfolio includes antibiotics, anti-inflammatory drugs, analgesics, and nutritional supplements in various dosage forms.
Business Model
The company generates revenue by selling pharmaceutical products through a network of distributors and medical representatives to healthcare providers across India.
Growth Outlook
Growth is driven by the expansion of its distribution network and the continued demand for essential pharmaceutical formulations within the domestic Indian market.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality control standards and evolving pharmaceutical regulations in India.
- Market Competition. As a small-cap entity, the company operates in a highly competitive pharmaceutical landscape with numerous established players.
- Supply Chain Disruptions. Dependence on a distribution network makes the company vulnerable to logistical challenges and supply chain inefficiencies.
- Pricing Pressures. Government-mandated price controls on essential medicines may impact profit margins and revenue growth.
Start your research today
Unlock AI insights, financials, peers and live data on Amwill Health Care Limited and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Amwill Health Care LimitedAMWILL | ₹87 Cr | — | — | — | 29.0% | — | — | -21.7% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Financials
Amwill Health Care Limited
BSE: AMWILL · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Amwill Health Care Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Amwill Healthcare is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of diverse pharmaceutical formulations. Its product portfolio includes antibiotics, anti-inflammatory drugs, analgesics, and nutritional supplements in various dosage forms.
Business Model
The company generates revenue by selling pharmaceutical products through a network of distributors and medical representatives to healthcare providers across India.
Growth Outlook
Growth is driven by the expansion of its distribution network and the continued demand for essential pharmaceutical formulations within the domestic Indian market.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality control standards and evolving pharmaceutical regulations in India.
- Market Competition. As a small-cap entity, the company operates in a highly competitive pharmaceutical landscape with numerous established players.
- Supply Chain Disruptions. Dependence on a distribution network makes the company vulnerable to logistical challenges and supply chain inefficiencies.
- Pricing Pressures. Government-mandated price controls on essential medicines may impact profit margins and revenue growth.
Start your research today
Unlock AI insights, financials, peers and live data on Amwill Health Care Limited and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026